Zobrazeno 1 - 10
of 266
pro vyhledávání: '"I. Diop-Mar"'
Autor:
D. Leboulleux, P. Coursaget, I. Diop-Mar, M. T. Diop, A.M. Coll-Seck, B. Yvonnet, M. Soumare, O. Bao, P. Le Cann, J. P. Chiron
Publikováno v:
Journal of Gastroenterology and Hepatology. 8:S128-S133
Hepatitis B virus (HBV) infection and related diseases represent some of the major public health problems in Senegal. The prevalence of hepatitis B surface antigen (HBsAg) in infants increased steadily during their first years of life. HBsAg prevalen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20dd6be71c446266e90aff16b53d566b
https://doi.org/10.1111/j.1440-1746.1993.tb01673.x
https://doi.org/10.1111/j.1440-1746.1993.tb01673.x
Autor:
J. P. Chiron, I. Diop-Mar, C. Bourdil, O. Bao, C. Molinie, Y. Buisson, P. Coursaget, M. T. Diop, B. Yvonnet
Publikováno v:
Research in Virology. 141:563-570
Antibodies to the preS1-encoded sequence of hepatitis B virus (HBV) envelope were detected by ELISA using a synthetic peptide analogue of preS1 proteins, in different groups of HBV-infected subjects and also in hepatitis B vaccine recipients. Such an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88f2c9143fd20253714693482392f469
https://doi.org/10.1016/0923-2516(90)90087-y
https://doi.org/10.1016/0923-2516(90)90087-y
Publikováno v:
Vaccine. 13:109-111
Previous studies have shown an absence of interaction between hepatitis B (HB) vaccine and other vaccines used in EPI programmes except for an apparent decrease of yellow fever antibody levels when hepatitis B and yellow fever vaccines are given simu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3d5a669005fcb64e6bc95797bf5742
https://doi.org/10.1016/0264-410x(95)80020-e
https://doi.org/10.1016/0264-410x(95)80020-e
Autor:
C. Bourdil, J. P. Chiron, Marie-Pascale Frenkiel, B. Yvonnet, Pierre Coursaget, S. Guindo, E. Jeannée, L. Teulières, Edgar H. Relyveld, A. Brizard, I. Diop-Mar, B. Fritzell
Publikováno v:
Vaccine. 10:319-321
In most developing countries, hepatitis B virus is endemic and prevention has to be carried out early in life and on a mass scale. In these regions, simultaneous administration of multiple antigens is normal practice. We have therefore investigated t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b83a9cc9de3b7a75fccb3da8155bf18
https://doi.org/10.1016/0264-410x(92)90370-y
https://doi.org/10.1016/0264-410x(92)90370-y
Autor:
R. N'Doye, C. Molinie, Y. Busson, J. Chotard, C. Bourdil, J. P. Chiron, I. Diop-Mar, B. Yvonnet, Pierre Coursaget
Publikováno v:
Vaccine. 8:S15-S17
A new type of hepatitis B virus (HBV) infection has been encountered in Senegalese infants and French adults characterized by serum hepatitis B surface antigen (HBsAg) without antibodies to the core antigen (anti-HBc). As the infection is not associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::929b7ae64a8c40f2c098f7c3aed28b9b
https://doi.org/10.1016/0264-410x(90)90208-4
https://doi.org/10.1016/0264-410x(90)90208-4
Autor:
Pierre Le Cann, I. Diop-Mar, B. Yvonnet, Anna-Marie Coll-Seck, Masserigné Soumare, D. Leboulleux, J. P. Chiron, Pierre Coursaget
Publikováno v:
Journal of hepatology. 21(2)
Numerous studies have documented the efficacy and safety of plasma-derived and recombinant hepatitis B vaccines. However, little is known about the long-term protection of hepatitis B vaccine, when anti-HBs declines to low or undetectable levels. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2368c43035bef2ede804100675566f24
https://pubmed.ncbi.nlm.nih.gov/7989718
https://pubmed.ncbi.nlm.nih.gov/7989718
Publikováno v:
Vaccine. 11(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ad5262e8c56545119c3303af6959d5d
https://pubmed.ncbi.nlm.nih.gov/8470435
https://pubmed.ncbi.nlm.nih.gov/8470435
Autor:
J. P. Chiron, L. Bringer, Pierre Coursaget, C. Blondeau, C. Bourdil, E. Jeannée, G. Sarr, S. Guindo, B. Yvonnet, I. Diop-Mar, B. Fritzell
Publikováno v:
Vaccine. 10(6)
Three doses of hepatitis B vaccine were given at 2, 4 and 9 months of age to 220 Senegalese infants living in the Dakar area of Senegal. Half of the infants received 5 micrograms plasma-derived hepatitis B vaccine (Hevac B) and the remainder 20 micro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ae5435f1554be69cdca941cfc72a4c
https://pubmed.ncbi.nlm.nih.gov/1534640
https://pubmed.ncbi.nlm.nih.gov/1534640
Autor:
Pierre Coursaget, Chunjie Wang, B. Yvonnet, I. Diop-Mar, Nicholas E. Day, W R Gilks, Chiron Jp
Publikováno v:
Lancet (London, England). 337(8751)
Studies have shown that to maintain protection against infection after a primary course of hepatitis B immunisation, revaccination can be scheduled on the basis of an anti-hepatitis B virus surface antigen (anti-HBs) titre obtained 1 month after the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3465edd352429d81b672aeb3d4c7585e
https://pubmed.ncbi.nlm.nih.gov/1677140
https://pubmed.ncbi.nlm.nih.gov/1677140
Autor:
J. P. Chiron, P. Coursaget, Kastally R, J. Perrin, I. Diop-Mar, O. Bao, B. Yvonnet, F. Ntareme, C. Bourdil, Z. Rampanarivo
Publikováno v:
Research in virology. 141(4)
Anti-hepatitis-C-virus (anti-HCV) antibody was tested for in sera from 410 adults living in Tunisia, Senegal, Burundi and Madagascar, and in 209 Tunisian and Senegalese patients suffering from liver diseases. Anti-HCV antibodies were detected in 4.2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6abcef1f1201bf4c48402ef6d27d3b
https://pubmed.ncbi.nlm.nih.gov/1964239
https://pubmed.ncbi.nlm.nih.gov/1964239